Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects
- PMID: 19606227
- PMCID: PMC2707617
- DOI: 10.1371/journal.pone.0006284
Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects
Abstract
Background: Prior economic evaluations of adult and adolescent vaccination strategies against pertussis have reached disparate conclusions. Using static approaches only, previous studies failed to analytically include the indirect benefits derived from herd immunity as well as the impact of vaccination on the evolution of disease incidence over time.
Methods: We assessed the impact of different pertussis vaccination strategies using a dynamic compartmental model able to consider pertussis transmission. We then combined the results with economic data to estimate the relative cost-effectiveness of pertussis immunization strategies for adolescents and adults in the US. The analysis compares combinations of programs targeting adolescents, parents of newborns (i.e. cocoon strategy), or adults of various ages.
Results: In the absence of adolescent or adult vaccination, pertussis incidence among adults is predicted to more than double in 20 years. Implementing an adult program in addition to childhood and adolescent vaccination either based on 1) a cocoon strategy and a single booster dose or 2) a decennial routine vaccination would maintain a low level of pertussis incidence in the long run for all age groups (respectively 30 and 20 cases per 100,000 person years). These strategies would also result in significant reductions of pertussis costs (between -77% and -80% including additional vaccination costs). The cocoon strategy complemented by a single booster dose is the most cost-effective one, whereas the decennial adult vaccination is slightly more effective in the long run.
Conclusions: By providing a high level of disease control, the implementation of an adult vaccination program against pertussis appears to be highly cost-effective and often cost-saving.
Conflict of interest statement
Figures


Similar articles
-
Pertussis immunization of adolescents in the United States: an economic evaluation.Pediatr Infect Dis J. 2005 May;24(5 Suppl):S75-82. doi: 10.1097/01.inf.0000160918.72953.51. Pediatr Infect Dis J. 2005. PMID: 15876932
-
Cost effectiveness of pertussis vaccination in adults.Am J Prev Med. 2007 Mar;32(3):186-193. doi: 10.1016/j.amepre.2006.10.016. Am J Prev Med. 2007. PMID: 17296470
-
Pertussis in adolescents and adults: should we vaccinate?Pediatrics. 2005 Jun;115(6):1675-84. doi: 10.1542/peds.2004-2509. Pediatrics. 2005. PMID: 15930232
-
A critical literature review of health economic evaluations in pertussis booster vaccination.Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):71-94. doi: 10.1586/erp.11.94. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22280198 Review.
-
Economic considerations for pertussis booster vaccination in adolescents.Pediatr Infect Dis J. 2005 Jun;24(6 Suppl):S127-33. doi: 10.1097/01.inf.0000166160.23976.35. Pediatr Infect Dis J. 2005. PMID: 15931140 Review.
Cited by
-
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.Hum Vaccin Immunother. 2012 Dec 1;8(12):1875-81. doi: 10.4161/hv.22083. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032160 Free PMC article. Clinical Trial.
-
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.J Pediatric Infect Dis Soc. 2019 May 11;8(2):105-114. doi: 10.1093/jpids/pix113. J Pediatric Infect Dis Soc. 2019. PMID: 29438562 Free PMC article. Clinical Trial.
-
Economic analysis of three interventions of different intensity in improving school implementation of a government healthy canteen policy in Australia: costs, incremental and relative cost effectiveness.BMC Public Health. 2018 Mar 20;18(1):378. doi: 10.1186/s12889-018-5315-y. BMC Public Health. 2018. PMID: 29558931 Free PMC article. Clinical Trial.
-
Prevention of pertussis through adult vaccination.Hum Vaccin Immunother. 2015;11(7):1744-7. doi: 10.1080/21645515.2015.1038442. Hum Vaccin Immunother. 2015. PMID: 25912733 Free PMC article. Review.
-
Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?Hum Vaccin Immunother. 2018;14(9):2263-2273. doi: 10.1080/21645515.2018.1474315. Epub 2018 Jun 22. Hum Vaccin Immunother. 2018. PMID: 29771574 Free PMC article.
References
-
- Edwards KM, Decker M. Pertussis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines, Fourth edition. Philadelphia, United States: Saunders; 2004. pp. 471–528.
-
- Pertussis deaths–United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51:616–618. - PubMed
-
- Pertussis–United States, 1997–2000. MMWR Morb Mortal Wkly Rep. 2002;51:73–76. - PubMed
-
- Pertussis–United States, 2001–2003. MMWR Morb Mortal Wkly Rep. 2005;54:1283–1286. - PubMed
-
- Jajosky RA, Hall PA, Adams DA, Dawkins FJ, Sharp P, et al. Summary of notifiable diseases–United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;53:1–79. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical